U.S. FDA approved first Respiratory Syncytial Virus (RSV) vaccine
On May 3, 2023, the U.S. FDA approved GlaxoSmithKline’s Arexvy as the first respiratory syncytial virus (RSV) vaccine approved for use in the United States.
Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Tags:
Source: U.S. Food and Drug Administration
Credit:
